• 1
    Galasko CS. Skeletal metastases. Clin Orthop 1986; 210: 1830.
  • 2
    Berrettoni BA, Carter JR. Mechanisms of cancer metastasis to bone. J Bone Joint Surg Am 1986; 68: 30812.
  • 3
    Yoneda T, Michigami T, Yi B, Williams PJ, Niewolna M, Hiraga T. Actions of bisphosphonate on bone metastasis in animal models of breast carcinoma. Cancer 2000; 88: 297988.
  • 4
    Jung A, Bornand J, Mermillod B, Edouard C, Meunier PJ. Inhibition by diphosphonates of bone resorption induced by the Walker tumor of the rat. Cancer Res 1984; 44: 300711.
  • 5
    Wingen F, Eichmann T, Manegold C, Krempien B. Effects of new bisphosphonic acids on tumor-induced bone destruction in the rat. J Cancer Res Clin Oncol 1986; 111: 3541.
  • 6
    Leal CA, Shea M, Patterson JD, Hayes WC. Alendronate prevents strength loss from osseous metastatic defects in a rat model. Trans Orthop Res Soc 1995;210.
  • 7
    Nakai M, Mundy GR, Williams PJ, Boyce B, Yoneda T. A synthetic antagonist to laminin inhibits the formation of osteolytic metastases by human melanoma cells in nude mice. Cancer Res 1992; 52: 53959.
  • 8
    Sasaki A, Boyce BF, Story B, Wright KR, Chapman M, Boyce R, Mundy GR, Yoneda T. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res 1995; 55: 35517.
  • 9
    Mbalaviele G, Dunstan CR, Sasaki A, Williams PJ, Mundy GR, Yoneda T. E-cadherin expression in human breast cancer cells suppresses the development of osteolytic bone metastases in an experimental metastasis model. Cancer Res 1996; 56: 406370.
  • 10
    Yoneda T, Sasaki A, Dunstan C, Williams PJ, Bauss F, De Clerck YA, Mundy GR. Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2. J Clin Invest 1997; 99: 250917.
  • 11
    Hiraga T, Williams PJ, Mundy GR, Yoneda T. The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases. Cancer Res 2001; 61: 441824.
  • 12
    Liotta LA, Wewer U, Rao NC, Schiffmann E, Stracke M, Guirguis R, Thorgeirsson U, Muschel R, Sobel M. Biochemical mechanisms of tumor invasion and metastasis. Anticancer Drug Des 1987; 2: 195202.
  • 13
    Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991; 64: 32736.
  • 14
    Wewer UM, Taraboletti G, Sobel ME, Albrechtsen R, Liotta LA. Role of laminin receptor in tumor cell migration. Cancer Res 1987; 47: 56918.
  • 15
    Kjonniksen I, Winderen M, Bruland O, Fodstad, O. Validity and usefulness of human tumor models established by intratibial cell inoculation in nude rats. Cancer Res 1994; 54: 17159.
  • 16
    Cailleau R, Young R, Olive M, Reeves WJ Jr. Breast tumor cell lines from pleural effusions. J Natl Cancer Inst 1974; 53: 66174.
  • 17
    Mühlbauer RC, Bauss F, Schenk R, Janner M, Bosies E, Strein K, Fleisch H. BM 21.0955, a potent new bisphosphonate to inhibit bone resorption. J Bone Miner Res 1991; 6: 100311.
  • 18
    Bauss F, Minne HW, Sterz H, Weng U, Wesch H, Ziegler R. Comparative bone analysis via inflammation-mediated osteopenia (IMO) in the rat. Calcif Tissue Int 1985; 37: 53946.
  • 19
    Juraschek M, Seibel MJ, Woitge HW, Krempien B, Bauss F. Association between histomorphometry and biochemical markers of bone turnover in a longitudinal rat model of parathyroid hormone-related peptide (PTHrP)–mediated tumor osteolysis. Bone 2000; 26: 47583.
  • 20
    Helger R, Rindfrey H, Hilgenfeldt J. Direct estimation of creatinine in serum and in urine without deproteinization using a modified Jaffe method. Z Klin Chem Klin Biochem 1974; 12: 3449.
  • 21
    Tietz N, Rinker A, Shaw LM. IFCC methods for the measurement of catalytic concentration of enzymes. Part 5. IFCC method for alkaline phosphatase (orthophosphoric-monoester phosphohydrolase, alkaline optimum, EC J Clin Chem Clin Biochem 1983; 21: 73148.
  • 22
    Pratt DA, Daniloff Y, Duncan A, Robins SP. Automated analysis of the pyridinium crosslinks of collagen in tissue and urine using solid-phase extraction and reversed-phase high-performance liquid chromatography. Anal Biochem 1992; 207: 16875.
  • 23
    van der Pluijm G, Vloedgraven H, van Beek E, Wee-Pals L, Lowik C, Papapoulos S. Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest 1996; 98: 698705.
  • 24
    Boissier S, Ferreras M, Peyruchaud O, Magnetto S, Ebetino FH, Colombel M, Delmas P, Delaisse JM, Clezardin P. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 2000; 60: 294954.
  • 25
    Fromigué O, Lagneaux L, Body JJ. Bisphosphonates induce breast cancer cell death in vitro. J Bone Miner Res 2000; 15: 221121.
  • 26
    Kjonniksen I, Nesland JM, Pihl A, Fodstad O. Nude rat model for studying metastasis of human tumor cells to bone and bone marrow. J Natl Cancer Inst 1990; 82: 40812.
  • 27
    Guise TA, Yin JJ, Taylor SD, Kumagai Y, Dallas M, Boyce BF, Yoneda T, Mundy GR. Evidence for a causal role of parathyroid hormone–related protein in the pathogenesis of human breast cancer–mediated osteolysis. J Clin Invest 1996; 98: 15449.
  • 28
    Rolstad B, Fossum S, Bazin H, Kimber I, Marshall J, Sparshott SM, Ford WL. The rapid rejection of allogeneic lymphocytes by a non-adaptive, cell- mediated mechanism (NK activity). Immunology 1985; 54: 12738.
  • 29
    Hougen HP. The athymic nude rat. Immunobiological characteristics with special reference to establishment of non-antigen-specific T-cell reactivity and induction of antigen-specific immunity. APMIS Suppl 1991; 21: 139.
  • 30
    Lin Y, Vandeputte M, Waer M. Natural killer cell and macrophage-mediated rejection of concordant xenografts in the absence of T and B cell responses. J Immunol 1997; 158: 565867.
  • 31
    Drewinko B, Moskwa P, Lotzova E, Trujillo JM. Successful heterotransplantation of human colon cancer cells to athymic animals is related to tumor cell differentiation and growth kinetics and to host natural killer cell activity. Invasion Metastasis 1986; 6: 6982.
  • 32
    Olden K. Human tumor bone metastasis model in athymic nude rats. J Natl Cancer Inst 1990; 82: 3401.
  • 33
    Shapses SA, Weissmann C, Seibel MJ, Chowdhury BS. Urinary pyridinium crosslink excretion is increased in critically ill surgical patients. Crit Care Med 1997; 25: 8590.
  • 34
    Shipman CM, Rogers MJ, Apperley JF, Russell RG, Croucher PI. Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. Br J Haematol 1997; 98: 66572.
  • 35
    Shipman CM, Croucher PI, Russell RG, Helfrich MH, Rogers MJ. The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res 1998; 58: 52947.
  • 36
    Aparicio A, Gardner A, Tu Y, Savage A, Berenson J, Lichtenstein A. In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia 1998; 12: 2209.
  • 37
    Senaratne SG, Pirianov G, Mansi JL, Arnett TR, Colston KW. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 2000; 82: 145968.
  • 38
    Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, Mundy GR, Boyce BF. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 1995; 10: 147887.
  • 39
    Mundy G, Yoneda T. Bisphosphonates as anticancer drugs. N Engl J Med 1998; 339: 398400.
  • 40
    Yoneda T, Williams PJ, Myoi A, Michigami T, Mbalaviele G. Cellular and molecular mechanisms of development of skeletal metastases. In: BodyJ-J, ed. Tumor bone diseases and osteoporosis in cancer patients. New York: Marcel Dekker, 2000. 4169.
  • 41
    Boissier S, Magnetto S, Frappart L, Cuzin B, Ebetino FH, Delmas PD, Clezardin P. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res 1997; 57: 38904.
  • 42
    Kurth AH, Kim SZ, Sedlmeyer I, Hovy L, Bauss F. Treatment with ibandronate preserves bone in experimental tumour-induced bone loss. J Bone Joint Surg Br 2000; 82: 12630.